Clinical trial
Dolutegravir Expanded Access Study
NCT01536873
Study timeline
Study start (actual)2012-06-14Date precision: day
Registry last updated2020-09-30
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Infection, Human Immunodeficiency Virusunresolved
HIV Infectionsunresolved
Interventions
DolutegravirDRUG · verified · RxNorm: dolutegravir
Sponsors & collaborators
ViiV Healthcarelead sponsor
GlaxoSmithKlinecollaborator
Mapped research locations
ParisFrance7ChicagoIllinois, United States3Rio de JaneiroBrazil3HoustonTexas, United States2Fort LauderdaleFlorida, United States2New YorkNew York, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1TorontoOntario, Canada1San FranciscoCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01536873 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.